Review of: "[Case Study] Targeting the Warburg Effect with the Glucose Mutation Theory: A Case Study of 36-Year-Old Female Treated for Stage IV Metastatic TPBCUsing Glucosodiene Over a 15-Day Period"

Jose Luís Fachi[1]

1 Washington University, Saint Louis

Potential competing interests: No potential competing interests to declare.

Here, the authors explored the potential of Glucosodiene as a therapeutic intervention for metastatic Triple-Positive Breast Cancer (TPBC). The case study involved a 36-year-old female patient with a family history of cancer. Facing complications during initial treatment, the authors commenced oral administration of Glucosodiene at a daily dosage of 100 ml over 15 consecutive days. Subsequent examinations through PET scans and biomarker monitoring revealed notable improvements in the patient's condition following Glucosodiene therapy, underscoring its promise as a primary therapeutic agent for aggressive forms of breast cancer.

While the study exhibits clarity and a well-structured design, several inquiries remain unanswered. As a "case study" report, the work appears fitting for potential acceptance. However, I suggest that the authors enhance the introduction by providing more comprehensive information about Glucosodiene. Additionally, it would be beneficial to emphasize in the conclusion that despite the observed efficacy, significant gaps persist in our understanding of Glucosodiene's mechanisms of action, particularly concerning its role in TPBC treatment.